FRAMINGHAM, Mass., June 29 /PRNewswire/ -- Boston Heart Lab, a pioneer in specialized diagnostics for patients with heart disease, was named "Most Promising Early Stage Company" by Silicom Ventures at the angel investment organization's 2009 Investment Summit, which took place June 2-3, 2009, at Stanford University in California. A four-judge panel selected Boston Heart Lab after evaluating the 20 participating companies for quality of management, vision, execution abilities, and the potential scope of the opportunities. Boston Heart Lab Chief Executive Officer, Wolfgang Daum, Ph.D., accepted the award on behalf of the start-up company, which has seen strong revenues since it began clinical operations in August 2008.

"We're very honored to receive this prestigious award, which is a testament both to the important work our Boston Heart Lab team has done to develop and launch our advanced cardiovascular diagnostic and lipid-testing program, and to the relevance of the services we provide to the marketplace," said Dr. Daum. "While there are other providers of esoteric testing for cardiology, we employ the most-advanced technology available with our proprietary two-dimensional gel electrophoresis of HDL particles and plasma sterol analysis. We deliver clinicians a more complete picture of the patient's health status -- our test results and analyses are the critical building blocks for a personalized treatment plan designed to offer patients the best opportunity for improved health outcomes. This includes more than 35 proprietary tests to assess the patient's cardiac health and risk profile, and a treatment algorithm (Boston Heart Navigator) based on the latest peer-reviewed scientific data."

Commenting on the award, Silicom Ventures' Founder and Managing Director, Gadi Behar, said, "The 2009 Investment Summit showcased 20 impressive early-stage companies in various fields -- from alternative energy and social networking to life sciences. The four-judge panel was unanimous in choosing Boston Heart Lab for its top award in recognition of the start-up's early success in turning the promise of personalized medicine into a reality for cardiac patients. There are 19 million people in the U.S. alone with established heart disease (patients who have had heart attack or stroke) that could benefit from Boston Heart Lab's services, not to mention the 45 million at-risk for cardiac disease. Boston Heart Lab's work will become increasingly important as our healthcare system focuses more and more on outcomes-based medicine to save health dollars and improve outcomes for patients." The judges for the award were three angel investors with extensive investment experience and a venture capitalist partner from Claremont Creek Ventures.

Silicom Ventures is one of the leading angel investment organizations in the United States. It links experienced investors (high-tech executives) and venture capitalists with entrepreneurs from around the globe and helps individual angels pool their efforts to gain access to better ventures and better investment deals. Silicom Ventures is leveraging its large network of investors, venture capitalists, industry executives, and technology experts offering entrepreneurs a highly effective screening and early funding process. Beyond funding, Silicom Ventures connects qualified companies with potential business partners, employers, and employees, and technical, professional, and business advisors.

Boston Heart Lab enables cardiologists and other clinicians to prescribe personalized treatment plans for cardiovascular disease and lipid disorders that offer patients the best opportunity for improved health outcomes, based on a panel of tests that provides the most comprehensive assessment available detailing the cause and state of the patient's disease. The company's proprietary two-dimensional gel electrophoresis of HDL particles reveals the entire reverse cholesterol metabolism (HDL) to sub classify the disease; while its proprietary plant sterol analysis evaluates how well the patient produces and absorbs cholesterol. Boston Heart Lab currently offers more than 35 proprietary, state-of-the-art tests to assess the patient's cardiac health and risk profile, and a treatment algorithm for developing a tailored treatment protocol (Boston Heart Navigator) based on the latest peer-reviewed scientific data. A privately held company, Boston Heart Lab began clinical operations after receiving its CLIA license in July 2008.

(Date:12/8/2016)... , Dec. 8, 2016 Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...